

Consolidated Financial Results for FY2024 (from April 1, 2024 to March 31, 2025) <Based on Japanese GAAP>

May 12, 2025

Company name: ASKA Pharmaceutical Holdings Co., Ltd.
 Stock exchange listing: Tokyo
 Stock code: 4886 URL: <https://www.aska-pharma-hd.co.jp/english/>
 Representative : President and Representative Director Takashi Yamaguchi
 Inquiries : Corporate Planning Department Director Manabu Ichikawa TEL +81-3-5484-8366
 Scheduled date of ordinary general meeting of shareholders : June 24, 2025
 Scheduled date to file Annual Securities Report : June 20, 2025
 Scheduled date to commence dividend payments : June 25, 2025
 Supplementary material for financial results : Yes
 Financial results meeting : Yes

(Amounts less than one million yen are rounded down)

1. Consolidated financial results for FY2024 (from April 1, 2024 to March 31, 2025)

(1) Consolidated operating result Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Year ended March 31, 2025	64,139	2.1	5,331	(18.0)	5,107	(21.7)	5,101	(32.4)
Year ended March 31, 2024	62,843	3.9	6,500	27.3	6,522	24.6	7,545	78.0

Note: Comprehensive income Year ended March 31, 2025 (Millions of yen) 5,222 (35.7)%
 Year ended March 31, 2024 (Millions of yen) 8,127 35.8%

	Earnings per share	Diluted earnings per share	Profit attributable to owners of parent/equity	Ordinary profit/total assets	Operating profit/net sales
	Yen	Yen	%	%	%
Year ended March 31, 2025	179.95	—	8.0	5.3	8.3
Year ended March 31, 2024	266.51	—	13.0	7.3	10.3

Reference: Equity Gains Year ended March 31, 2025 (Millions of yen) (53)
 (Losses) of Affiliated Companies Year ended March 31, 2024 (Millions of yen) (41)

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
As of March 31, 2025	100,534	69,195	65.0	2,302.61
As of March 31, 2024	90,745	61,930	68.2	2,186.10

Reference: Tangible net worth Year ended March 31, 2025 (Millions of yen) 65,310
 Year ended March 31, 2024 (Millions of yen) 61,930

(3) Consolidated cash

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Year ended March 31, 2025	2,485	(6,124)	(2,956)	10,603
Year ended March 31, 2024	1,486	1,706	(3,943)	16,738

2. Cash dividends

	Annual dividends per share					Total cash dividends (Total)	Dividend payout ratio (Consolidated)	Ratio of dividends to net assets (Consolidated)
	1st quarter-end	2nd quarter-end	3rd quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Year ended March 31, 2024	—	20.00	—	20.00	40.00	1,133	15.0	1.9
Year ended March 31, 2025	—	25.00	—	30.00	55.00	1,560	30.6	2.5
Year ending March 31, 2026 (Forecast)	—	27.00	—	28.00	55.00		30.0	

Note. Revision from the dividend forecast currently announced: Yes

3. Forecast of consolidated financial results for FY2025 (from April 1, 2025 to March 31, 2026)

Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	75,000	16.9	6,800	27.5	6,800	33.1	5,200	1.9	183.44